Serum and stomach tissue levels of geranylgeranylacetone in patients.
The serum concentration of geranylgeranylacetone (GGA) was estimated in four patients with peptic ulcer following oral administration of a 100-mg dose. The area under the serum concentration-time curve (AUC) after oral dosing of the patients 30 min after a meal was 30- to 45-fold larger than that in the fasted state. Distribution of GGA in the stomach removed surgically from the patients was also examined after oral administration of 50 mg thrice daily for 1-13 days prior to surgery. The tissue level of GGA in the ulcer region was higher than that in the surrounding normal region.
D000284:Administration, Oral; D000897:Anti-Ulcer Agents / Q000378:metabolism*; D001682:Biological Availability; D004224:Diterpenes / Q000097:blood / Q000378:metabolism*; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D008297:Male; D010437:Peptic Ulcer / Q000188:drug therapy / Q000378:metabolism*
D000897:Anti-Ulcer Agents; D004224:Diterpenes; C031049:geranylgeranylacetone